Back to News
Oct 22, 2025 4:00 AM

Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance

Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline®

Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosion of Somatuline® and accelerated sales growth of the rest of the portfolio: total sales growth of around 10.0%2 at CER (prior guidance greater than 7.0%); core operating margin of around 35.0% of total sales (prior guidance greater than 32.0%)

Announcement today of the proposed acquisition of ImCheck Therapeutics bringing a first-in-class Phase II asset, expanding pipeline in oncology

PARIS, FRANCE, 22 October 2025 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year to date and the third quarter of 2025.

 

YTD 2025

YTD 2024

% change

Q3 2025

Q3 2024

% change

 

€m

€m

Actual

CER

€m

€m

Actual

CER

Oncology

1,912.0

1,829.8

4.5 %

6.6 %

624.0

604.0

3.3 %

7.0 %

Rare Disease

255.4

129.7

97.0 %

101.0 %

102.0

50.8

100.8 %

109.1 %

Neuroscience

567.3

536.4

5.8 %

9.5 %

188.9

181.9

3.9 %

9.1 % ...